29.09.2023 • News

Ineos Acquires the Eastman Texas City Site

Petrochemicals giant Ineos has agreed to buy compatriot Eastman’s Texas City site, including the 600 kt acetic acid plant and all associated third party activities on the site, for about $500 million.

The two companies have also signed a memorandum of understanding (MoU) to explore options for a long-term supply agreement for vinyl acetate monomer.

David Brooks, CEO of Ineos Acetyls, commented: "We are delighted to announce this strategic acquisition which will help drive our global ambition for our Acetyls business. The site is ideally placed to take advantage of competitively priced feedstocks which will help support the growth of our business and sustainable future of the site."

Currently Ineos licenses its Cativa acetic acid technology to Eastman at Texas City for the production of acetic acid at the site.

“We are happy to have reached this agreement with Ineos. They have been a strong partner with us at the Texas City site and have extensive experience and a complementary position in the acetyls space,” said Erwin Dijkman, president of Eastman’s division Chemical Intermediates.

“Our Texas City Operations is an attractive site with an incredible team of people, and we are pleased that Ineos plans to further invest in and grow the site. We look forward to working closely with Ineos as we prepare for a seamless transition later this year, and longer-term as operators of our plasticizer assets at the site,” Dijkman added.

All current employees on the Eastman Texas City site will be transferred to Ineos upon completion of the transaction. The plasticizers unit on the site will continue to be owned by Eastman but will be operated and maintained by Ineos from closing.

The deal is expected to close before the end of 2023, subject to regulatory approvals.

Ineos Acquires the Eastman Texas City Site

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read